Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) issued its earnings results on Tuesday. The biotechnology company reported ($2.93) earnings per share for the quarter, beating the consensus estimate of ($3.77) by $0.84, Zacks reports. The firm had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period last year, the business earned ($16.50) EPS.
Atara Biotherapeutics Stock Performance
Shares of ATRA opened at $12.77 on Friday. The company’s 50 day simple moving average is $8.95 and its 200-day simple moving average is $10.32. Atara Biotherapeutics has a 12-month low of $6.50 and a 12-month high of $39.50.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the stock. Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and dropped their price objective for the company from $25.00 to $18.00 in a research report on Friday, August 16th. Canaccord Genuity Group raised their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $16.67.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
Further Reading
- Five stocks we like better than Atara Biotherapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
- 3 Fintech Stocks With Good 2021 Prospects
- Why Meta Should Rally All The Way Into 2025
- The Basics of Support and Resistance
- 3 High-Yields Unfazed by the Election: Altria, Truist, Verizon
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
